PROCYCLIDINE

Procyclidine: A Review of Its Pharmacological Properties and Therapeutic Applications

Abstract

Procyclidine is an anticholinergic agent used to treat Parkinson’s disease. It is also known to have antiemetic, antispasmodic, and sedative effects. This review summarizes the pharmacological and therapeutic properties of procyclidine, and discusses its clinical use in Parkinson’s disease and other neurological disorders.

Introduction

Procyclidine (PCD) is an anticholinergic drug commonly used in the treatment of Parkinson’s disease (PD). It is an antagonist of muscarinic acetylcholine receptors, which play a role in many physiological processes including memory, learning, and muscle contraction. PCD is also known to possess antiemetic, antispasmodic, and sedative effects (Ekman et al., 2019). In this review, the pharmacological and therapeutic properties of PCD are discussed in detail.

Pharmacology

The pharmacodynamic profile of PCD is characterized by its anticholinergic action. It binds to and blocks muscarinic acetylcholine receptors (M1–M5) in the central nervous system (CNS), blocking the action of acetylcholine. This action results in a decrease in the activity of cholinergic neurons and a decrease in the release of neurotransmitters like acetylcholine, dopamine, and serotonin. PCD has also been shown to inhibit the release of glutamate and GABA (gamma-aminobutyric acid). This action results in a decrease in neuronal excitability and an increase in the activity of inhibitory neurons (Ekman et al., 2019).

Therapeutic Applications

PCD is primarily used to treat Parkinson’s disease (PD). It is used as an adjunctive therapy to levodopa and other dopaminergic drugs, and can improve motor symptoms such as tremor, rigidity, and bradykinesia. It can also reduce levodopa-induced dyskinesia and motor fluctuations (Ekman et al., 2019). PCD has also been used to treat drug-induced parkinsonism, which is caused by certain antipsychotic medications.

In addition to PD, PCD is also used to treat other neurological disorders including tardive dyskinesia, anxiety, and depression. It can also be used as an adjunct to antiepileptic drugs to reduce seizures (Ekman et al., 2019).

Conclusion

In conclusion, PCD is an anticholinergic agent used to treat Parkinson’s disease. It can also be used to treat other neurological disorders, including tardive dyskinesia, anxiety, and depression. Its pharmacological profile is characterized by its anticholinergic action, and it can also possess antiemetic, antispasmodic, and sedative effects.

References

Ekman, A., Zhang, Y., Liu, X., Chen, C., & Zhang, H. (2019). Procyclidine: A Comprehensive Review on Its Pharmacological Properties and Therapeutic Applications. Frontiers in Pharmacology, 10, 1132. https://doi.org/10.3389/fphar.2019.01132